We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A federal appellate court has ruled in favor of Sanofi-Aventis’s defense of its combination hypertension drug Tarka, finding that there was nothing “obvious” about its patent on the product. Read More
Two Johnson & Johnson divisions have sued generic firm Mylan over its bid to market a version of the attention deficit hyperactivity disorder drug Concerta. Read More
Specialty pharmaceutical firm Actavis has reached a deal to market generic versions of Valeant Pharmaceuticals’ acne-treating Acanya Gel, as well as its hypertension drug Tiazac, under a patent settlement agreement announced Monday. Read More
Shire Pharmaceuticals said it will acquire Lumena Pharmaceuticals for at least $265 million, making it the latest drugmaker to turn to new treatments for rare diseases as a means to offset losses from generic competition. Read More
The FDA has been quicker to approve new active substances over the last decade than both its European and Japanese counterparts, a recent study finds. Read More
Sun Pharma is in the midst of another quality problem, this time involving a massive recall of 428,058 bottles of antihistamines and antidepressants after stability testing found issues with the products. Read More